Current status of allogeneic hematopoietic stem cell transplantation for treatment of peripheral T-cell lymphoma / 白血病·淋巴瘤

ABSTRACT

Peripheral T-cell lymphoma (PTCL) is a kind of heterogeneous neoplasms mostly with strong invasiveness, a tendency of recurrence and drug resistance and poor prognosis. Five year disease-free-survival (DFS) rate of PTCL is less than 30% under the treatment setting of chemotherapy and autologous stem cell transplantation. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a role of a graft-versus-lymphoma effect in the treatment of PTCL, meanwhile, long DFS rate of allo-HSCT for the treatment of relapsed and refractory PTCL reaches 35%-50%. Therefore, allo-HSCT is an effective treatment method for PTCL patients.